144 related articles for article (PubMed ID: 20094687)
1. Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD.
Gani R; Griffin J; Kelly S; Rutten-van Mölken M
Prim Care Respir J; 2010 Mar; 19(1):68-74. PubMed ID: 20094687
[TBL] [Abstract][Full Text] [Related]
2. [Cost-effectiveness analysis of tiotropium compared to ipratropium and salmeterol].
García Ruiz AJ; Leiva Fernández F; Martos Crespo F
Arch Bronconeumol; 2005 May; 41(5):242-8. PubMed ID: 15919004
[TBL] [Abstract][Full Text] [Related]
3. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.
Oostenbrink JB; Rutten-van Mölken MP; Monz BU; FitzGerald JM
Value Health; 2005; 8(1):32-46. PubMed ID: 15841892
[TBL] [Abstract][Full Text] [Related]
4. A UK-based cost-utility analysis of indacaterol, a once-daily maintenance bronchodilator for patients with COPD, using real world evidence on resource use.
Price D; Asukai Y; Ananthapavan J; Malcolm B; Radwan A; Keyzor I
Appl Health Econ Health Policy; 2013 Jun; 11(3):259-74. PubMed ID: 23529714
[TBL] [Abstract][Full Text] [Related]
5. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain.
Rutten-van Mölken MP; Oostenbrink JB; Miravitlles M; Monz BU
Eur J Health Econ; 2007 Jun; 8(2):123-35. PubMed ID: 17370096
[TBL] [Abstract][Full Text] [Related]
6. Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease.
Dalal AA; Roberts MH; Petersen HV; Blanchette CM; Mapel DW
Int J Chron Obstruct Pulmon Dis; 2010 Dec; 6():13-22. PubMed ID: 21311689
[TBL] [Abstract][Full Text] [Related]
7. [Economic value of tiotropium in the treatment of chronic obstructive pulmonary disease].
Schramm W; Haake D; Brandt A
Praxis (Bern 1994); 2005 Nov; 94(46):1803-10. PubMed ID: 16329401
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease.
Oba Y
Mayo Clin Proc; 2007 May; 82(5):575-82. PubMed ID: 17493425
[TBL] [Abstract][Full Text] [Related]
9. Which long-acting bronchodilator is most cost-effective for the treatment of COPD?
Hoogendoorn M; Kappelhoff BS; Overbeek JA; Wouters EF; Rutten-van Mölken MP
Neth J Med; 2012 Oct; 70(8):357-64. PubMed ID: 23065983
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial.
Hoogendoorn M; Al MJ; Beeh KM; Bowles D; Graf von der Schulenburg JM; Lungershausen J; Monz BU; Schmidt H; Vogelmeier C; Rutten-van Mölken MP
Eur Respir J; 2013 Mar; 41(3):556-64. PubMed ID: 22700844
[TBL] [Abstract][Full Text] [Related]
11. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease.
Oostenbrink JB; Rutten-van Mölken MP; Al MJ; Van Noord JA; Vincken W
Eur Respir J; 2004 Feb; 23(2):241-9. PubMed ID: 14979498
[TBL] [Abstract][Full Text] [Related]
12. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
Keam SJ; Keating GM
Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
[TBL] [Abstract][Full Text] [Related]
13. Healthcare costs associated with initial maintenance therapy with fluticasone propionate 250 μg/salmeterol 50 μg combination versus anticholinergic bronchodilators in elderly US Medicare-eligible beneficiaries with COPD.
Dalal AA; Petersen H; Simoni-Wastila L; Blanchette CM
J Med Econ; 2009; 12(4):339-47. PubMed ID: 19827993
[TBL] [Abstract][Full Text] [Related]
14. Clinical and economic outcomes in an observational study of COPD maintenance therapies: multivariable regression versus propensity score matching.
Roberts MH; Dalal AA
Int J Chron Obstruct Pulmon Dis; 2012; 7():221-33. PubMed ID: 22500122
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in Greece.
Maniadakis N; Tzanakis N; Fragoulakis V; Hatzikou M; Siafakas N
Curr Med Res Opin; 2006 Aug; 22(8):1599-607. PubMed ID: 16870084
[TBL] [Abstract][Full Text] [Related]
16. Using cost-effectiveness analysis to sharpen formulary decision-making: the example of tiotropium at the Veterans Affairs health care system.
Onukwugha E; Mullins CD; DeLisle S
Value Health; 2008; 11(5):980-8. PubMed ID: 18194405
[TBL] [Abstract][Full Text] [Related]
17. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD.
Brusasco V; Hodder R; Miravitlles M; Korducki L; Towse L; Kesten S
Thorax; 2003 May; 58(5):399-404. PubMed ID: 12728159
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD.
Najafzadeh M; Marra CA; Sadatsafavi M; Aaron SD; Sullivan SD; Vandemheen KL; Jones PW; Fitzgerald JM
Thorax; 2008 Nov; 63(11):962-7. PubMed ID: 18621985
[TBL] [Abstract][Full Text] [Related]
19. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease.
Welsh EJ; Cates CJ; Poole P
Cochrane Database Syst Rev; 2013 May; (5):CD007891. PubMed ID: 23728670
[TBL] [Abstract][Full Text] [Related]
20. Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD.
Price D; Gray A; Gale R; Asukai Y; Mungapen L; Lloyd A; Peters L; Neidhardt K; Gantner T
Respir Med; 2011 Nov; 105(11):1635-47. PubMed ID: 21764277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
